Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18101349 | 0.85 | CYP11B1 (0.38) | CYP11B1CYP11B2NR3C2UGT2B17NISCH | |
| SCHEMBL18101348 | 0.84 | CYP11B1 (0.37) | CYP11B1CYP11B2NR3C2UGT2B17NISCH | |
| SCHEMBL20341727 | 0.84 | FFAR1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL18094374 | 0.84 | FFAR1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL15287108 | 0.78 | CYP11B1 (0.37) | CYP11B1CYP11B2NR3C2S1PR1S1PR2 | |
| SCHEMBL35211487 | 0.78 | CYP11B1 (0.37) | CYP11B1CYP11B2NR3C2S1PR1S1PR2 | |
| SCHEMBL15021555 | 0.78 | CYP11B1 (0.37) | CYP11B1CYP11B2NR3C2S1PR1S1PR2 | |
| SCHEMBL18094358 | 0.69 | FFAR1 (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL16800695 | 0.68 | FFAR1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL20341734 | 0.68 | FFAR1 (0.42) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957219-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280626-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | CYP11B1 245/4885CYP11B2 249/4885NR3C2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.